Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis

Francesco Muratore, Nicolò Pipitone, Gene G. Hunder, Carlo Salvarani

Research output: Contribution to journalArticle

Abstract

Glucocorticoids are highly effective in treating polymyalgia rheumatica and giant cell arteritis, but their use is associated with numerous adverse events. Therefore, it is important to use them for the shortest period of time possible. The published evidence suggests that discontinuation of GCis feasible in a substantial number of patients with polymyalgia rheumaticaand giant cell arteritis after an adequate period of treatment, provided that glucocorticoids are tapered gradually. Recurrences are relatively infrequent in polymyalgia rheumatica and somewhat more common in giant cell arteritis. Immunosuppressive agents may be used in patients with frequently relapsing or recurring disease to decrease exposure to glucocorticoids.

Original languageEnglish
JournalClinical and Experimental Rheumatology
Volume31
Issue numberSUPPL.78
Publication statusPublished - 2013

Keywords

  • Discontinuation of therapy
  • Giant cell arteritis
  • Glucocorticoids
  • Polymyalgia rheumatica

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis'. Together they form a unique fingerprint.

  • Cite this

    Muratore, F., Pipitone, N., Hunder, G. G., & Salvarani, C. (2013). Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis. Clinical and Experimental Rheumatology, 31(SUPPL.78).